This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 26/1/124    most recent 01.ATV.0000194073.87647.10v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by den Boer, M. A.M. Articles by Romijn, J. A. Search for Related Content PubMed PubMed Citation Articles by den Boer, M. A.M. Articles by Romijn, J. A. Related Collections Animal models of human disease Risk Factors Energy metabolism Genetically altered mice Lipid and lipoprotein metabolism Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:124.)
© 2006 American Heart Association, Inc.

Vascular Biology

Ritonavir Impairs Lipoprotein Lipase–Mediated Lipolysis and Decreases Uptake of Fatty Acids in Adipose Tissue

Marion A.M. den Boer; Jimmy F.P. Berbée; Peter Reiss; Marc van der Valk; Peter J. Voshol; Folkert Kuipers; Louis M. Havekes; Patrick C.N. Rensen; Johannes A. Romijn

From the Departments of Endocrinology and Diabetes (M.A.M.d.B., P.J.V., J.A.R.), General Internal Medicine (J.F.P.B., L.M.H., P.C.N.R.), and Cardiology (L.M.H.), Leiden University Medical Center, Leiden; Netherlands Organization for Applied Scientific Research-Quality of Life (M.A.M.d.B., J.F.P.B., P.J.V., L.M.H., P.C.N.R.), Leiden; Department of Infectious Diseases, Tropical Medicine, and AIDS (P.R., M.v.d.V.), Amsterdam Medical Center, Amsterdam; and Laboratory of Pediatrics (F.K.), Center for Liver, Digestive, and Metabolic Diseases, University Hospital Groningen, Groningen, the Netherlands.

Correspondence to Marion A.M. den Boer, Department of Endocrinology and Diabetes, LUMC, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail A.M.den_Boer{at}lumc.nl

Objective— The use of the HIV protease inhibitor ritonavir (RTV) is frequently associated with hypertriglyceridemia and lipodystrophy. The aim of our study was to determine the mechanism underlying the observed hypertriglyceridemia.

Methods and Results— Feeding female APOE*3-Leiden transgenic mice a Western-type diet supplemented with RTV (35 mg/kg per day) for 2 weeks resulted in a 2-fold increase in fasting plasma triglyceride (TG) levels, which was specific for very low–density lipoprotein (VLDL). RTV did not change the hepatic VLDL-TG production. Instead, RTV did increase the postprandial TG response to an oral fat load (area under the curve, 25.5±12.1 versus 13.8±6.8 mmol/L per hour in controls; P<0.05). Likewise, RTV hampered the plasma clearance of intravenously injected glycerol tri[³H]oleate-labeled VLDL–like emulsion particles (half time, 19.3±10.5 versus 5.0±1.3 minutes in controls; P<0.05) associated with a decrease of 44% in plasma lipoprotein lipase activity. Accordingly, RTV decreased the uptake of TG-derived fatty acids (FAs) into adipose tissue, as well as the uptake of albumin-bound FA.

Conclusions— We conclude that RTV causes hypertriglyceridemia via decreased lipoprotein lipase–mediated clearance of VLDL-TG. In addition, RTV specifically impairs the uptake of FA in adipose tissue, which may contribute to the lipodystrophy that is frequently observed in HIV-infected subjects on antiretroviral therapy.

We investigated the mechanism underlying the hypertriglyceridemia associated with ritonavir treatment in APOE*3-Leiden mice. Ritonavir increased the postprandial triglyceride response and decreased the clearance of glycerol tri[3H]oleatelabeled very low density lipoprotein-like emulsion particles, as related to decreased plasma lipoprotein lipase activity. These effects were accompanied by decreased fatty acid flux into adipose tissue.

Key Words: dyslipidemia • protease inhibitor • transgenic mice • FA metabolism • TG metabolism

Related Article:

HIV Protease Inhibitors and Hyperlipidemia: A Fatty Acid Connection

Arthur A. Spector
Arterioscler. Thromb. Vasc. Biol. 2006 26: 7-9. [Full Text] [PDF]

This article has been cited by other articles:

				M. J. Carper, W. T. Cade, M. Cam, S. Zhang, A. Shalev, K. E. Yarasheski, and S. Ramanadham HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E558 - E567. [Abstract] [Full Text] [PDF]

				J. T. Rodgers and P. Puigserver Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1 PNAS, July 31, 2007; 104(31): 12861 - 12866. [Abstract] [Full Text] [PDF]

				H. Zhou, E. C. Gurley, S. Jarujaron, H. Ding, Y. Fang, Z. Xu, W. M. Pandak Jr., and P. B. Hylemon HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1071 - G1080. [Abstract] [Full Text] [PDF]

				M. Guardiola, R. Ferre, J. Salazar, C. Alonso-Villaverde, B. Coll, S. Parra, L. Masana, and J. Ribalta Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5-1131T->C Gene Variation Clin. Chem., October 1, 2006; 52(10): 1914 - 1919. [Abstract] [Full Text] [PDF]

				C. G. Morse and J. A. Kovacs Metabolic and skeletal complications of HIV infection: the price of success. JAMA, August 16, 2006; 296(7): 844 - 854. [Abstract] [Full Text] [PDF]

				A. A. Spector HIV Protease Inhibitors and Hyperlipidemia: A Fatty Acid Connection Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 7 - 9. [Full Text] [PDF]